Market capitalization | $386.05m |
Enterprise Value | $181.73m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 14.75 |
P/S ratio (TTM) P/S ratio | 31.34 |
P/B ratio (TTM) P/B ratio | 0.97 |
Revenue growth (TTM) Revenue growth | -89.67% |
Revenue (TTM) Revenue | $12.32m |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
18 Analysts have issued a Fate Therapeutics, Inc. forecast:
18 Analysts have issued a Fate Therapeutics, Inc. forecast:
Jun '24 |
+/-
%
|
||
Revenue | 12 12 |
90%
90%
|
|
Gross Profit | -6.85 -6.85 |
107%
107%
|
|
EBITDA | -176 -176 |
22%
22%
|
EBIT (Operating Income) EBIT | -196 -196 |
19%
19%
|
Net Profit | -176 -176 |
17%
17%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products include immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
Head office | United States |
CEO | J. Wolchko |
Employees | 181 |
Founded | 2007 |
Website | www.fatetherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.